![]() |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Liste des catégories
AlcoolismeAlzheimer Et ParkinsonAnalgésiquesAnti-inflammatoiresAntiallergiquesAntibiotiquesAnticonvulsivantsAntidépresseursAntifongiquesAntiparasitairesAntivirauxArthriteAsthmeCancerChirurgieCholestérolContraceptifsDiabèteDiurétiquesDysfonction érectileHypertension ArtérielleMaladies CardiovasculairesMigrainesObésitéOstéoporoseRelaxants MusculairesSanté FéminineSanté MasculineSoins De La PeauSoins Des YeuxTractus Gastro-intestinalTroubles MentauxTroubles NeurologiquesV I HVoies RespiratoiresVoies Urinaires 17 May 2012 15:31:29
South Africa exceeds 2007-11 treatment targets by 50%South Africa exceeds 2007-11 treatment targets by 50% aidsmap Crude estimates of numbers of public sector patients on treatment in each quarter were calculated according to lamivudine (3TC, Epivir ) sales figures from Aspen Pharmacare, which supplied 80% of lamivudine to the public sector until recently.
08 May 2012 22:15:42
Risk of Liver-Related Deaths Twice as High With Chronic Hep B Versus Hep CRisk of Liver-Related Deaths Twice as High With Chronic Hep B Versus Hep C AIDSmeds.com HIV AIDS Treatment News ... is â a potential beneficial effect of the use of HBV-active agentsâ â notably Viread, Emtriva (emtricitabine), Truvada (tenofovir plus emtricitabine) or Epivir (lamivudine)â â as part of combination antiretroviral therapy in HBV-infected individuals.â
26 Apr 2012 17:21:18
Revisiting DynavaxRevisiting Dynavax RTT News Some of the FDA-approved drugs to treat hepatitis B, include, Schering-Plough's Intron A, Roche's Pegasys, GlaxoSmithKline's Epivir , Gilead Sciences' Hepsera and Bristol-Myers Squibb's Baraclude, to name a few. However, there is no cure for chronic ...
26 Apr 2012 12:52:09
GlaxoSmithKline net profit dips by 12% in Q1GlaxoSmithKline net profit dips by 12% in Q1 pharmabiz.com ViV Healthcare turnover declined by 5 per cent as the effect of recent launches of generic competitors in the US to Combivir and Epivir offset the growth of newer products. Andrew Witty, CEO, said, â We remain mindful of the challenges we face given the ...
|
|
Choose Your language:
Recherche sur le site
Testimonials
Cher monsieur,
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Bestsellers|Politique|Questions fréquentes|Testimonials|Contactez-nous|Sitemap |
|
|
|
|
| |